OncoZenge AB (8LY) Stock Statistics & Valuation Metrics

OncoZenge AB has a market cap or net worth of €6.51M. The enterprise value is ―.

OncoZenge AB has 11,713,244 shares outstanding. The number of shares has decreased by -2.65% in one year.

OncoZenge AB’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

The current PE Ratio of OncoZenge AB is -2.28. OncoZenge AB’s PEG ratio is -1.08.

In the last 12 months, OncoZenge AB had revenue of 3.00K and earned -15.90M in profits. Earnings per share was -1.36.

In the last 12 months, operating cash flow was -8.76M and capital expenditures 0.00, giving a free cash flow of -8.76M billion.

OncoZenge AB pays an annual dividend of ―, resulting in a dividend yield of ―

OncoZenge AB upcoming earnings date is May 20, 2025, TBA Not Confirmed.

OncoZenge AB as a current ratio of 7.94, with Debt / Equity ratio of 0.00%

In the past 12 months, OncoZenge AB has paid 0.00 in taxes.

OncoZenge AB EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.

OncoZenge AB has €3.86M in cash and marketable securities with kr0.00 in debt, giving a net cash position of -€3.86M billion.

Gross margin is 100.00%, with operating margin of -530066.67%, and net profit margin of -530066.67%.

The average price target for OncoZenge AB is ―, which is 11.43% higher than the current price. The consensus rating is ―